Search Press releases Keywords From To 13 Apr 2023 UCB’s Rozanolixizumab and Zilucoplan Phase 3 Generalized Myasthenia Gravis studies published in prestigious The Lancet Neurology Journal Read More 24 Mar 2023 Acquisition of own shares Read More 18 Mar 2023 Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks Read More 17 Mar 2023 Acquisition of own shares Read More 16 Mar 2023 UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis and Hidradenitis Suppurativa Read More 15 Mar 2023 Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington's Disease Read More Pagination First page Previous page Previous … Page 8 Page 9 Page 10 Page 11 Current page 12 Page 13 Page 14 Page 15 Page 16 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
